COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 07/2020 - Coloplast strengthens Executive Management

Coloplast A/S - Announcement no. 07/2020 - Coloplast strengthens Executive Management

Coloplast strengthens Executive Management to deliver on upcoming 2025 strategy centred around innovation and growth

Today, the Board of Directors have decided to expand the Executive Leadership Team from four members to six members as of 1 October 2020.

The expansion aims to support the upcoming strategy which will focus on innovation and growth. A new Innovation Executive Vice President position position with responsibility for the company’s commercial offering and combining marketing, R&D and select global functions will be led by Nicolai Buhl Andersen. A new Growth Executive Vice President position position which combines the chronic care sales organization and the Wound & Skin care SBU will be led by Paul Marcun. Finally, HR is renamed People & Culture and elevated to the Executive leadership team to be led by Camilla G. Møhl.

Nicolai Buhl Andersen is appointed Executive Vice President, Innovation and member of the Executive Leadership Team. Since joining Coloplast in 2005, Nicolai has held various senior management roles in the company including Head of Ostomy Care, Head of Sales, Nordic Region and Commercial Excellence. For the last 10 years, Nicolai has been SVP, Global Wound Care. Nicolai holds a Master's degree in Economics and Marketing from Copenhagen Business School and Sophia University, Japan.

Camilla G. Møhl is appointed Senior Vice President, People & Culture and member of the Executive Leadership Team. Since joining Coloplast in 2016, Camilla has been VP, Global HR Commercial Organization and was promoted to VP Global HR in 2019. Prior to joining Coloplast, Camilla gained more than 15 years’ experience within HR at large international companies including Carlsberg and Mars. Camilla holds a Master’s degree in Human Resources Management from Copenhagen Business School.

“We are currently in the process of finalising our 2025 strategy, which will be launched at our Capital Markets Day at the end of September. As we look towards 2025, and strive to continue to deliver value for our shareholders, users, employees, healthcare professionals and partners, Innovation and Growth will be key strategic themes. To set ourselves up to deliver on our 2025 strategy, we’ve decided to expand our Executive Leadership Team and create new roles to match these strategic themes. I am happy to welcome Nicolai and Camilla to the team. Strong, passionate leaders, with strong followership, who live and breathe the Coloplast values,” says President & CEO Kristian Villumsen.

“By expanding the Coloplast Executive Leadership Team, we are taking the first steps to secure a successful execution of the company’s 2025 strategy. Innovation and growth have characterised Coloplast for more than 60 years, and I am confident that this leadership team is well-equipped to deliver solid growth and life-changing innovations in the years to come,” says Chairman Lars Rasmussen.

As of 1 October 2020, the Executive Leadership Team will consist of:

President & CEO, Kristian Villumsen

Executive Vice President, Innovation, Nicolai Buhl Andersen

Executive Vice President & CFO, Anders Lonning-Skovgaard

Executive Vice President, Growth, Paul Marcun

Senior Vice President, People & Culture, Camilla G. Møhl

Executive Vice President, Global Operations, Allan Rasmussen

Lars Rasmussen

Chairman of the Board 



For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Ellen Bjurgert

Vice President, Investor Relations

Tel. / 4911 3376

E-mail

Rasmus Sørensen

Senior Manager, Investor Relations

Tel. / 4911 1786

E-mail

Press and the media

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

Tel.

E-mail

Website

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebæk

Denmark

Business reg. (CVR) no. 69749917 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-08.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

EN
18/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast annoncerer ændringer i ledelsesteamet

Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...

 PRESS RELEASE

Coloplast announces changes to Executive Leadership Team

Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...

 PRESS RELEASE

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...

 PRESS RELEASE

Coloplast A/S - Decisions at the Annual General Meeting 2025

Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...

 PRESS RELEASE

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025 Indkaldelse til ordinær generalforsamling 2025 Den ordinære generalforsamling i Coloplast A/S afholdes torsdag den 4. december 2025 kl. 15:30 på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark. Indkaldelsen til den ordinære generalforsamling er vedlagt.     For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardExecutive Vice President, CFOTlf. 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTlf. 4911 1800 / 4911 3266Email: Simo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch